<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03317457</url>
  </required_header>
  <id_info>
    <org_study_id>AIO-STS-0415</org_study_id>
    <secondary_id>2016-004750-15</secondary_id>
    <nct_id>NCT03317457</nct_id>
  </id_info>
  <brief_title>Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma</brief_title>
  <acronym>MEDISARC</acronym>
  <official_title>A Randomized Phase II Study of Durvalumab (MEDI4736) and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIO-Studien-gGmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AIO-Studien-gGmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the trial is to assess the efficacy of Durvalumab and Tremelimumab in&#xD;
      comparison to doxorubicin in treatment-naïve Soft tissue sarcoma patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 15, 2017</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Treatment Arm A: Combination of Durvalumab and Tremelimumab Treatment Arm B: Doxorubicin</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>up to 57 months from randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AEs / SAEs and Treatment Emergent Adverse Events according to CTCAE 4.03</measure>
    <time_frame>up to 18 months from randomization</time_frame>
    <description>Assessment of adverse events of tremelimumab and durvalumab (MEDI4736) combination therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) according to RECIST 1.1 criteria</measure>
    <time_frame>up to 57months from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS mile stone rate at 24 months</measure>
    <time_frame>up to 24 months from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>up to 57 months from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival (PFS)</measure>
    <time_frame>up to 57 months from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life QLQ-C30</measure>
    <time_frame>up to 12 months from randomization</time_frame>
    <description>scores according to EORTC QLQ-C30 scoring manual (Quality of life)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Metastatic Adult Soft Tissue Sarcoma</condition>
  <condition>Recurrent Adult Soft Tissue Sarcoma</condition>
  <arm_group>
    <arm_group_label>Durvalumab and Tremelimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycles/courses 1-3:&#xD;
Durvalumab 1.5g q4wks Tremelimumab 75 mg q4wks&#xD;
Cycles/courses ≥4:&#xD;
Durvalumab 1.5g q4wks Tremelimumab 75 mg q12wks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doxorubicin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Doxorubicin 75 mg/qm q3wks for 6 courses</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Durvalumab and Tremelimumab</intervention_name>
    <description>immun checkpoint inhibitor</description>
    <arm_group_label>Durvalumab and Tremelimumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Anthracycline</description>
    <arm_group_label>Doxorubicin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Written informed consent and any locally-required authorization (EU Data Privacy&#xD;
             Directive in the EU) obtained from the subject prior to performing any&#xD;
             protocol-related procedures, including screening evaluations 2. Age ≥ 18 years at time&#xD;
             of study entry 3. Body weight &gt; 30kg at study inclusion 4. Histologically confirmed&#xD;
             diagnosis of metastatic or advanced soft tissue sarcoma of intermediate or high grade&#xD;
             [according to FNCLCC score; intermediate=grade 2 score of 4-5 points, high grade =&#xD;
             grade 3 score of 6-8 points] with disease progression within 6 months prior to study&#xD;
             inclusion:&#xD;
&#xD;
             • Fibrosarcoma&#xD;
&#xD;
             • Pleomorphic high grade sarcoma (&quot;malignant fibrous histiocytoma&quot;)&#xD;
&#xD;
             • Leiomyosarcoma&#xD;
&#xD;
               -  Liposarcoma (myxoid liposarcoma, dedifferentiated liposarcoma, pleomorphic&#xD;
                  liposarcoma)&#xD;
&#xD;
               -  Malignant glomus tumor&#xD;
&#xD;
               -  Rhabdomyosarcoma, alveolar or pleomorphic (excluding embryonal)&#xD;
&#xD;
               -  Vascular sarcoma (angiosarcoma)&#xD;
&#xD;
               -  Synovial sarcoma&#xD;
&#xD;
               -  High-grade sarcoma, not otherwise specified (NOS)&#xD;
&#xD;
               -  Malignant peripheral nerve sheath tumors&#xD;
&#xD;
               -  Other types of sarcoma (not listed as ineligible), if approved by the&#xD;
                  coordinating investigator / study coordinator.&#xD;
&#xD;
        Excluding:&#xD;
&#xD;
        Uncertain differentiation (epithelioid, alveolar soft part, clear cell, desmoplastic small&#xD;
        round cell, malignant mesenchymoma, PEComa), chondrosarcoma, Ewing sarcomas/PNET, chordoma,&#xD;
        malignant solitary fibrous tumors, embryonal rhabdomyosarcoma, osteosarcoma,&#xD;
        gastrointestinal stromal tumors, dermatofibrosarcoma protuberans, inflammatory&#xD;
        myofibroblastic sarcoma (low-grade), neuroblastoma, malignant mesothelioma, and mixed&#xD;
        mesodermal tumors of the uterus (Study inclusion is based on local histopathological&#xD;
        diagnosis). 5. Metastatic or locally advanced STS, not amendable to surgery with curative&#xD;
        intention.&#xD;
&#xD;
        6. No prior treatment line for advanced or metastatic disease. 7. ECOG performance status&#xD;
        0-2 8. Patients with measurable disease (at least one uni-dimensionally measurable target&#xD;
        lesion by CT-scan or MRI) according to Response Evaluation Criteria in Solid Tumors (RECIST&#xD;
        1.1) are eligible.&#xD;
&#xD;
        9. If prior palliative radiotherapy has been given to metastatic lesions: either ≥1&#xD;
        measurable lesion remains outside the radition field or the sole lesion meets RECIST 1.1&#xD;
        criteria for progression at study entry.&#xD;
&#xD;
        10. Patients with bone lesions as the only measurable lesion are eligible, provided that&#xD;
        lesions consist of soft tissue, which is measurable via CT or MRI.&#xD;
&#xD;
        11. Prior radiotherapy and surgery are allowed if completed 4 weeks (for minor surgery and&#xD;
        palliative radiotherapy for bone pain: 2 weeks) prior to start of treatment and patient&#xD;
        recovered from toxic effects.&#xD;
&#xD;
        12. Adequate blood count, liver-enzymes, and renal function:&#xD;
&#xD;
          -  Haemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L (&gt; 1500 per mm3)&#xD;
&#xD;
          -  Platelet count ≥ 100 x 109/L (&gt;100,000 per mm3)&#xD;
&#xD;
          -  Serum bilirubin ≤ 1.5 x ULN. This will not apply to subjects with confirmed Gilbert's&#xD;
             syndrome (persistent or recurrent hyperbilirubinemia that is predominantly&#xD;
             unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed&#xD;
             only in consultation with their physician.&#xD;
&#xD;
          -  AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional upper limit of normal unless liver&#xD;
             metastases are present, in which case it must be ≤ 5x ULN&#xD;
&#xD;
          -  Serum creatinine CL&gt;40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault&#xD;
             1976) or by 24-hour urine collection for determination of creatinine clearance 13.&#xD;
             Adequate cardiac function (left ventricular ejection fraction ≥50% as assessed by&#xD;
             ECHO) 14. Female subjects must either be of non-reproductive potential (ie,&#xD;
             post-menopausal by history: ≥60 years old and no menses for ≥1 year without an&#xD;
             alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal&#xD;
             ligation, OR history of bilateral oophorectomy) or must have a negative serum&#xD;
             pregnancy test upon study entry.&#xD;
&#xD;
             15. Subject is willing and able to comply with the protocol for the duration of the&#xD;
             study including undergoing treatment and scheduled visits and examinations including&#xD;
             follow up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Patients who are suitable for anthracycline-based combination therapies 2. Cardiac&#xD;
             events such as arrhythmias, myocardial infarction, CHF, apoplexy, lung embolism within&#xD;
             6 months prior to study treatment 3. Mean QT interval corrected for heart rate (QTc)&#xD;
             ≥470 ms calculated from 3 electrocardiograms (ECGs) using Fredericia's correction 4.&#xD;
             Uncontrolled severe hypertension (failure of diastolic blood pressure to fall below&#xD;
             100 mmHg and systolic blood pressure &gt;160 mmHg) 5. Previous malignancy (other than&#xD;
             STS) which either progresses or requires active treatment.&#xD;
&#xD;
        Exceptions are: basal cell cancer of the skin, pre-invasive cancer of the cervix, T1a or&#xD;
        T1b prostate carcinoma, or superficial bladder tumor [Ta, Tis and T1].&#xD;
&#xD;
        6. History or clinical evidence of CNS metastases&#xD;
&#xD;
        Exceptions are: Subjects who have completed local therapy and who meet both of the&#xD;
        following criteria:&#xD;
&#xD;
          1. are asymptomatic and&#xD;
&#xD;
          2. have no requirement for steroids 6 weeks prior to start of study treament. Screening&#xD;
             with CNS imaging (CT or MRI) is required only if clinically indicated or if the&#xD;
             subject has a history of CNS metastases 7. Active or prior documented autoimmune&#xD;
             disease within the past 2 years. NOTE: Subjects with vitiligo, Grave's disease, or&#xD;
             psoriasis not requiring systemic treatment (within the past 2 years) are not excluded.&#xD;
&#xD;
             8. Active or prior documented inflammatory bowel disease (e.g., Crohn's disease,&#xD;
             ulcerative colitis) 9. History of primary immunodeficiency 10. History of allogeneic&#xD;
             organ transplant 11. History of hypersensitivity to durvalumab, tremelimumab (alone or&#xD;
             in combination), doxorubicin or any of the constituents of the products 12. Medication&#xD;
             that is known to interfere with any of the agents applied in the trial.&#xD;
&#xD;
             13. Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable&#xD;
             angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active&#xD;
             bleeding diatheses including any subject known to have evidence of acute or chronic&#xD;
             hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric&#xD;
             illness/social situations that would limit compliance with study requirements or&#xD;
             compromise the ability of the subject to give written informed consent.&#xD;
&#xD;
             14. Major surgical procedure (as defined by the Investigator) within 28 days prior to&#xD;
             the first dose of study medication. Note: Local surgery of isolated lesions for&#xD;
             palliative intent is acceptable.&#xD;
&#xD;
             15. Any unresolved toxicity &gt;CTCAE grade 2 from previous anti-cancer therapy with the&#xD;
             exception of alopecia, vitiligo, and the laboratory values defined in the inclusion&#xD;
             criteria.&#xD;
&#xD;
               -  Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis after&#xD;
                  consultation with the Coordinating Investigator.&#xD;
&#xD;
               -  Patients with irreversible toxicity not reasonably expected to be exacerbated by&#xD;
                  treatment with durvalumab or tremelimumab (if applicable) may be included only&#xD;
                  after consultation with the Coordinating Investigator.&#xD;
&#xD;
                  16. Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any&#xD;
                  previous immunotherapy agent, or any unresolved irAE &gt;Grade 1 17. Known history&#xD;
                  of previous clinical diagnosis of tuberculosis 18. Receipt of live attenuated&#xD;
                  vaccination within 30 days prior to study entry or within 30 days of receiving&#xD;
                  durvalumab 19. Female subjects who are pregnant, breast-feeding or male or female&#xD;
                  patients of reproductive potential who are not employing an effective method of&#xD;
                  birth control (failure rate of less than 1% per year) 20. Any condition that, in&#xD;
                  the opinion of the investigator, would interfere with evaluation of study&#xD;
                  treatment or interpretation of patient safety or study results 21. Participation&#xD;
                  in another clinical study with an investigational product during the last 30 days&#xD;
                  before inclusion 22. Any previous treatment with a PD-1 or PD-L1 or CTLA-4&#xD;
                  inhibitor, including durvalumab and tremelimunab 23. Current or prior use of&#xD;
                  immunosuppressive medication within 28 days before the first dose of durvalumab,&#xD;
                  with the exceptions of intranasal and inhaled corticosteroids or systemic&#xD;
                  corticosteroids at physiological doses, which are not to exceed 10 mg/day of&#xD;
                  prednisone, or an equivalent corticosteroid 24. Receipt of the last dose of&#xD;
                  anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted&#xD;
                  therapy, biologic therapy, tumor embolization, monoclonal antibodies, other&#xD;
                  investigational agent) ≤ 21 days prior to the first dose of study drug or ≤4&#xD;
                  half-lifes of the agent administered, which ever comes first.&#xD;
&#xD;
                  25. Previous enrollment or randomization in the present study (does not include&#xD;
                  screening failure).&#xD;
&#xD;
                  26. Patient who has been incarcerated or involuntarily institutionalized by court&#xD;
                  order or by the authorities (§ 40 Abs. 1 S. 3 Nr. 4 AMG).&#xD;
&#xD;
                  27. Patients who are unable to consent because they do not understand the nature,&#xD;
                  significance and implications of the clinical trial and therefore cannot form a&#xD;
                  rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG].&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Viktor Grünwald, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Essen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 18, 2017</study_first_submitted>
  <study_first_submitted_qc>October 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2017</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Tremelimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

